Literature DB >> 19029776

Usefulness and limitations of fluorine-18-fluorodeoxyglucose positron emission tomography for the detection of malignancy of orbital tumors.

Junichi Miyamoto1, Kazunori Tatsuzawa, Kei Owada, Takuya Kawabe, Hiroyasu Sasajima, Katsuyoshi Mineura.   

Abstract

Fluorine-18-fluorodeoxyglucose positron emission tomography ([18F]FDG PET) was assessed as a method for providing information about the malignancy of orbital tumors. Twelve patients with 13 orbital tumors underwent [18F]FDG PET followed by biopsy or tumor removal via a transcranial approach. The accumulation ratio between the tumor and the contralateral normal tissue (T/N ratio) was calculated for 10 of the 13 lesions. The T/N ratio in benign lesions was compared with that in malignant tumors. Histological examination identified 7 lesions as malignant: anaplastic astrocytoma of the optic nerve in 1 patient, which recurred as glioblastoma of the optic nerve, malignant lymphoma of mucosa-associated lymphoid tissue type in 1 patient, malignant melanoma in 1 patient, adenoid cystic carcinoma in 2 patients, and adenocarcinoma (unknown origin) in 1 patient. The T/N ratio was 1.06 +/- 0.03 (mean +/- standard deviation) in benign tumors, and significantly higher at 1.81 +/- 0.27 in malignant tumors (p = 0.0027). Both patterns of high and iso uptake of [18F]FDG were found in orbital pseudotumor. [18F]FDG PET can determine the malignancy of orbital tumors, but cannot distinguish malignant tumor from inflammatory disease such as pseudotumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029776     DOI: 10.2176/nmc.48.495

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  6 in total

1.  Novel window for cancer nanotheranostics: non-invasive ocular assessments of tumor growth and nanotherapeutic treatment efficacy in vivo.

Authors:  Mayank Goswami; Xinlei Wang; Pengfei Zhang; Wenwu Xiao; Sarah J Karlen; Yuanpei Li; Robert J Zawadzki; Marie E Burns; Kit S Lam; Edward N Pugh
Journal:  Biomed Opt Express       Date:  2018-12-11       Impact factor: 3.732

2.  Value of (18)F-FDG-PET/CT in ocular sebaceous adenocarcinoma: a case report and literature review.

Authors:  Xin Zhao; Guang-Fa Wang; Kui Zhao; Hong-Guang Cui; Wei Ding
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging.

Authors:  Bela S Purohit; Maria Isabel Vargas; Angeliki Ailianou; Laura Merlini; Pierre-Alexandre Poletti; Alexandra Platon; Bénédicte M Delattre; Olivier Rager; Karim Burkhardt; Minerva Becker
Journal:  Insights Imaging       Date:  2015-10-31

4.  Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics.

Authors:  Rajkumar Sadasivam; Gopinath Packirisamy; Snehlata Shakya; Mayank Goswami
Journal:  Nanotheranostics       Date:  2021-01-15

5.  Image findings of cranial nerve pathology on [18F]-2- deoxy-D-glucose (FDG) positron emission tomography with computerized tomography (PET/CT): a pictorial essay.

Authors:  Osama A Raslan; Razi Muzaffar; Vilaas Shetty; Medhat M Osman
Journal:  Cancer Imaging       Date:  2015-12-03       Impact factor: 3.909

6.  Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1.

Authors:  Patrick Combemale; Laurence Valeyrie-Allanore; Francesco Giammarile; Stephane Pinson; Bernard Guillot; Denis Mariano Goulart; Pierre Wolkenstein; Jean Yves Blay; Thomas Mognetti
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.